Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Erlanson

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|December 20, 2021
Fragment-to-Lead Medicinal Chemistry Publications in 2020Iwan J P de Esch, Daniel A Erlanson, Wolfgang Jahnke, et al.
Biochemistry|May 25, 2005
Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residueStig K Hansen, Mark T Cancilla, Timothy P Shiau, et al.
Journal of Medicinal Chemistry|November 22, 2018
Fragment-to-Lead Medicinal Chemistry Publications in 2017Paul N Mortenson, Daniel A Erlanson, Iwan J P de Esch, et al.
Journal of Medicinal Chemistry|January 9, 2020
Fragment-to-Lead Medicinal Chemistry Publications in 2018Daniel A Erlanson, Iwan J P de Esch, Wolfgang Jahnke, et al.
Journal of Medicinal Chemistry|January 9, 2023
Fragment-to-Lead Medicinal Chemistry Publications in 2021Louise Walsh, Daniel A Erlanson, Iwan J P de Esch, et al.
Nature Communications|December 18, 2025
A practical method for determining the rate of covalent modification of fragments and leadsJanice Jeon, Svetlana A Kholodar, Brian H Tran, et al.
Journal of Medicinal Chemistry|April 29, 2016
Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in AcademiaGyörgy M Keserű, Daniel A Erlanson, György G Ferenczy, et al.
Journal of Medicinal Chemistry|January 6, 2025
Fragment-to-Lead Medicinal Chemistry Publications in 2023Rhian S Holvey, Daniel A Erlanson, Iwan J P de Esch, et al.
Journal of Medicinal Chemistry|November 23, 2020
Fragment-to-Lead Medicinal Chemistry Publications in 2019Wolfgang Jahnke, Daniel A Erlanson, Iwan J P de Esch, et al.
Bioorganic & Medicinal Chemistry Letters|June 27, 2008
Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistryMark T Cancilla, Molly M He, Nina Viswanathan, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|December 20, 2021
Fragment-to-Lead Medicinal Chemistry Publications in 2020Iwan J P de Esch, Daniel A Erlanson, Wolfgang Jahnke, et al.
Biochemistry|May 25, 2005
Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residueStig K Hansen, Mark T Cancilla, Timothy P Shiau, et al.
Journal of Medicinal Chemistry|November 22, 2018
Fragment-to-Lead Medicinal Chemistry Publications in 2017Paul N Mortenson, Daniel A Erlanson, Iwan J P de Esch, et al.
Journal of Medicinal Chemistry|January 9, 2020
Fragment-to-Lead Medicinal Chemistry Publications in 2018Daniel A Erlanson, Iwan J P de Esch, Wolfgang Jahnke, et al.
Journal of Medicinal Chemistry|January 9, 2023
Fragment-to-Lead Medicinal Chemistry Publications in 2021Louise Walsh, Daniel A Erlanson, Iwan J P de Esch, et al.
Nature Communications|December 18, 2025
A practical method for determining the rate of covalent modification of fragments and leadsJanice Jeon, Svetlana A Kholodar, Brian H Tran, et al.
Journal of Medicinal Chemistry|April 29, 2016
Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in AcademiaGyörgy M Keserű, Daniel A Erlanson, György G Ferenczy, et al.
Journal of Medicinal Chemistry|January 6, 2025
Fragment-to-Lead Medicinal Chemistry Publications in 2023Rhian S Holvey, Daniel A Erlanson, Iwan J P de Esch, et al.
Journal of Medicinal Chemistry|November 23, 2020
Fragment-to-Lead Medicinal Chemistry Publications in 2019Wolfgang Jahnke, Daniel A Erlanson, Iwan J P de Esch, et al.
Bioorganic & Medicinal Chemistry Letters|June 27, 2008
Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistryMark T Cancilla, Molly M He, Nina Viswanathan, et al.
Pageof 5